Deep Sequencing for Viral Genetic Stability Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the neurotoxicity and genetic stability of poliovirus-derived therapeutics, such as PVS-RIPO, are inefficient and unreliable, particularly due to the high mutation rate of single-stranded RNA viruses and the limitations of in vitro sequencing techniques, which require time-consuming and costly in vivo primate neurovirulence testing.
Innovation Solution
A deep sequencing method involving RNA extraction from a master viral bank, digestion of host cell DNA using DNase, conversion to double-stranded cDNA, library preparation, and parallel sequencing to detect sequence variants, allowing for the analysis of viral genetic stability and uniformity with high sensitivity and accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If in vitro plaque-sequencing methods are used to verify viral genetic stability, then the method is simpler to perform, but the sensitivity is relatively poor and cannot detect rare genetic reversion mutations
Solution Approach 1:
The patent combines multiple testing functions (genomic sequencing, neurotoxicity assessment, and genetic stability verification) into a single NGS-based library. This integrated approach enables simultaneous detection of rare genetic mutations and evaluation of viral pathogenicity potential, achieving high sensitivity without requiring separate complex testing procedures
Solution Approach 2:
The patent introduces an in vivo NGS library as an intermediary medium that captures viral RNA from infected host cells. This library serves as a bridge between viral genetic material and sequencing analysis, enabling detection of rare mutations that would be missed by traditional in vitro methods while maintaining experimental simplicity
2Reliability
If in vivo primate neurovirulence testing is performed to ensure safety, then the reliability of safety assessment is improved, but the testing time requires several months and costs are high
Solution Approach 1:
The patent performs preliminary genetic screening using NGS to identify potential neurovirulence-risk mutations before conducting in vivo testing. By pre-filtering virus lots based on genetic stability and absence of critical mutations, the method reduces the number of animals required and shortens the overall testing timeline while maintaining safety assessment reliability
Solution Approach 2:
The patent implements a feedback mechanism where NGS data from viral populations is used to inform and adjust in vivo testing strategies. The high-sensitivity genetic data provides feedback on viral lot quality, allowing researchers to make informed decisions about which lots proceed to animal testing, thereby optimizing resource allocation and reducing testing duration
3Measurement precision
If traditional Sanger sequencing is used to analyze viral sequences, then the method is easier to implement, but the detection limit is approximately 15-20% variation per base and cannot detect rare variants
Solution Approach 1:
The patent transitions from traditional Sanger sequencing (single-dimensional, consensus-based) to NGS (multi-dimensional, population-based). This dimensional shift enables simultaneous analysis of multiple viral genomes in parallel, detecting rare mutations at frequencies as low as 1% or lower, while the user-friendly library preparation kits maintain ease of implementation
4Measurement precision
If deep sequencing methods are implemented to detect rare mutations, then the detection sensitivity is significantly improved, but the sequencing library preparation and analysis complexity increases
Solution Approach 1:
The patent employs disposable, commercially available NGS library preparation kits that streamline the complex process of library construction. These pre-optimized kits eliminate the need for custom protocol development and reduce hands-on complexity, enabling high-sensitivity deep sequencing with minimal operational burden
Solution Approach 2:
The patent utilizes self-service features of modern NGS platforms, including automated library preparation protocols, built-in quality control metrics, and user-friendly data analysis pipelines. These self-service capabilities handle the complexity of deep sequencing internally, allowing users to achieve high detection sensitivity without manually managing complex procedural steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables rapid and sensitive detection of genetic mutations in virus-derived therapeutics, replacing traditional testing methods with a more efficient and reliable validation of viral genetic stability, ensuring product safety and reducing the need for costly in vivo testing.
Implementation Method 1
contacting the extracted RNA with 4 U of DNase at 2U/μl for 20 - 40 minutes at 37°C under conditions that substantially digest host cell genomic DNA and host cell mitochondrial DNA, but do not substantially digest viral RNA molecules
Implementation Method 2
producing double-stranded cDNA from the enriched viral RNA using oligo(dT)x primers, thereby generating viral double-stranded cDNA
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein are massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines, including the PVS-RIPO vaccine. The methods allow for the determination of micro-heterogeneity and quantitation of low frequency sequence variants and in the case of PVS- RIPO, are expected to replace the monkey neurovirulence safety test (MNVT) and the mutant analysis by PCR and restriction enzyme cleavage (MAPREC) methods that are currently used to screen lots of RNA virus-derived therapeutics.